Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) EBITDA Margin (2016 - 2025)

Ani Pharmaceuticals' EBITDA Margin history spans 15 years, with the latest figure at 14.07% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1637.0% year-over-year to 14.07%; the TTM value through Dec 2025 reached 12.58%, up 1248.0%, while the annual FY2025 figure was 13.58%, 1228.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 14.07% at Ani Pharmaceuticals, down from 15.91% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 27.19% in Q1 2021 and bottomed at 38.94% in Q4 2021.
  • The 5-year median for EBITDA Margin is 4.43% (2024), against an average of 0.55%.
  • The largest YoY upside for EBITDA Margin was 4087bps in 2022 against a maximum downside of -5696bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 38.94% in 2021, then surged by 105bps to 1.93% in 2022, then soared by 165bps to 5.11% in 2023, then plummeted by -145bps to 2.3% in 2024, then skyrocketed by 713bps to 14.07% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's EBITDA Margin are 14.07% (Q4 2025), 15.91% (Q3 2025), and 6.57% (Q2 2025).